Rigel Pharmaceuticals | RIGL - Operating Profit


Rigel Pharmaceuticals reported $14.06M in Operating Profit for its fiscal quarter ending in September of 2024.





Operating Profit Change Date
Agenus USD 15.05M 656K Mar/2026
Amgen USD 4.68B 65M Sep/2026
Anika Therapeutics USD 646K 3.88M Dec/2025
Arrowhead Research USD -170.09M 28.83M Jun/2026
AstraZeneca USD 4.66B 1.5B Sep/2026
BioMarin Pharmaceutical USD 205.6M 100M Sep/2026
Bristol-Myers Squibb USD 255M 44M Sep/2026
Celldex Therapeutics USD -82.25M 1.63M Sep/2026
Daiichi Sankyo JPY 108.7B 23.6B Sep/2026
Eli Lilly USD 12.46B 2.68B Jun/2026
Halozyme Therapeutics USD -60.68M 3.04M Sep/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Intrexon USD -60.84M 26.62M Jun/2024
Ionis Pharmaceuticals USD -102.29M 15.71M Jun/2026
Karyopharm Therapeutics USD -26.76M 8.92M Mar/2026
Ligand Pharmaceuticals USD 54.53M 2.1M Sep/2026
MacroGenics USD -13.85M 19.59M Jun/2026
Neurocrine Biosciences USD 343M 123.1M Sep/2026
Pfizer USD 662M 5M Sep/2026
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Rigel Pharmaceuticals USD 14.06M 13.61M Sep/2024
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Ultragenyx Pharmaceutical USD -110M 35M Sep/2026
Veracyte USD 18.02M 5.94M Sep/2026